STaC Sponsored Events:
11-12th May 2015 :: Symposium and network event :: Antimicrobial Resistance in people, animals and environments: building inter-disciplinary capacity
Reed Hall, Streatham Campus
The Science, Technology and Culture (STAC) research theme at the University of Exeter will host a short symposium over two days with the following aims:
1. To develop cross-disciplinary understanding of the scientific and social scientific challenges of antimicrobial use and resistance with specific focus on agricultural uses and downstream management.
2. To communicate the areas and known extent of risks and uncertainties with respect to AMR and its impacts on human and animal health and the environment.
3. To foster research networks and teams with a view, in particular, to the third and fourth themes of the Antimicrobial Resistance Funders’ Forum (AMRFF) AMR Initiative: namely •Theme 3: Understanding the real world interactions. •Theme 4: Behaviour within and beyond the healthcare setting.
4. We are especially keen to debate and co-define the roles of social science within AMR and the food/ farming sector, with a focus on inputs from Science and Technology Studies, Animal Studies and Social Veterinary Studies .
Contact Steve Hinchliffe for further details: Stephen.Hinchliffe@exeter.ac.uk
21 May :: STAC Sponsored Lecture by Eben Kirksey (UNSW)
Other Events of Interest:
12 January 2015 15:00 :: Egenis Seminar :: “The changing natures of natural medicines, as seen by regulatory scientists” – Dr Jennifer Cuffe (University of Exeter)
Nature, as Raymond Williams remarked, “is perhaps the most complex word in the language” (1976). Nevertheless, the word (as a qualifier) was used, in Canada, to create a new legal category of commodified medicines: that of ‘natural health products.’ With this change in law, regulatory scientists were mandated to segregate out medicines that would be regulated as natural health products, from those that would continue to be regulated as drugs. Needless to say, which medicines should be considered natural for the purposes of regulation was not always self-evident. This paper takes an anthropological and historical approach to the question of how Canadian regulatory scientists have approached the “nature” in drugs. It takes an anthropological approach by describing how regulatory scientists approached their task of segregating out natural medicines when the new regulations were enacted. It then provides an overview of how plant-based medicines have been marketed and regulated through the twentieth century, to explain how the regulators were able to approach their classificatory task as they did. I argue that the current safety of natural health products is to some extent a self-fulfilling prophecy, because government officials, formally and informally, have progressively made the idea of a risky natural health product (according to regulatory practice) into an oxymoron since the early 1900s.
15 January 2015 15:00 :: NAMBIO Seminar :: “The Question of the Animal and Religion: Theoretical Stakes, Practical Implications – Aaron S. Gross (University of San Diego)
Building One, Syndicate Room B.
28 January 2015 15:00 :: Egenis Seminar :: “Human Nature, Human Processes, and Human Kinds” – Prof John Dupre (University of Exeter)
11 February 15:00 :: Egenis Seminar :: “The Wild-Indoors: The Room Spaces of Scientific Inquiry” – Dr Ann Kelly (University of Exeter)
18 February 2015 15:00 :: Egenis Seminar :: “Ethical harmonization across space: logistic and regulatory issues in implementing a multi-national clinical trial” Prof Christine Hauskeller and Dr Nicole-Kerstin Baur
In this talk we report findings from an empirical investigation of the process in which a stem cell clinical trial is being implemented across 10 European countries. As part of a clinical trial team, we had the unique opportunity to study implementation – including its events and problems – while it happened. Obstacles for swift patient recruitment across clinical sites arose for a variety of reasons, but most are related to the minute standardization of practice which is the basis for the scientific approach in medicine that identifies clinical trials as ultimate evidence for clinical efficacy. We identified differences in resource management and in locally entrenched daily routines of patient care, but also in the practical implementation of regulations and insurance requirements, for example, which as such relate back to specific understandings of best practice in clinical care. Our findings show that the policies developed to harmonise medical practice and clinical trials in Europe can lead to serious delays before patient recruitment even starts. We especially focus on problems with the logistics and technological requirements following European Medicines Agency (EMA) regulations and the effects of the Voluntary Harmonisation Procedure (VHP), a protocol aimed at simplifying multinational ethics approval of general agreements which depend on both trust and coherence in other policies.